On December 23, 2024, AstraZeneca PLC was sued for violations of the federal securities laws in the United States District Court for the Central District of California on behalf of investors who purchased or otherwise acquired publicly traded AstraZeneca securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.